quest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator
Company profile
Ticker
DGX
Exchange
Website
CEO
Stephen Rusckowski
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Laboratory Corp. Of America • Fortrea • Radnet • Akumin • Burning Rock Biotech • Guardant Health • Exact Sciences • Genomic Health • Invitae • Natera ...
Former names
CORNING CLINICAL LABORATORIES INC
SEC CIK
Corporate docs
Subsidiaries
100% Quest Diagnostics Holdings Incorporated • 100% Quest Diagnostics International Holdings Limited • 100% Quest Diagnostics Holdings Ltd. • 100% ExamOne Canada, Inc. • 99.9% Quest Diagnostics HTAS India Private Limited • 100% Quest Diagnostics of Puerto Rico, Inc. • 100% Quest Diagnostics Ireland Limited • 100% Quest Diagnostics (Shanghai) Co., Ltd. • 100% Quest Diagnostics Clinical Laboratories, Inc. • Solstas Lab Partners Group ...
IRS number
161387862
DGX stock data
Latest filings (excl ownership)
8-K
Quest Diagnostics Elects Robert B. Carter, CIO of FedEx Corporation, to Board of Directors
21 May 24
8-K
Amendments to Articles of Incorporation or Bylaws
21 May 24
10-Q
2024 Q1
Quarterly report
24 Apr 24
8-K
Results of Operations and Financial Condition
23 Apr 24
PX14A6G
Letter to shareholders
11 Apr 24
DEFA14A
Additional proxy soliciting materials
5 Apr 24
DEF 14A
Definitive proxy
5 Apr 24
PRE 14A
Preliminary proxy
25 Mar 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share
1 Feb 24
Transcripts
DGX
Earnings call transcript
2024 Q1
23 Apr 24
DGX
Earnings call transcript
2023 Q4
1 Feb 24
DGX
Earnings call transcript
2023 Q3
24 Oct 23
DGX
Earnings call transcript
2023 Q2
26 Jul 23
DGX
Earnings call transcript
2023 Q2
26 Jul 23
DGX
Earnings call transcript
2023 Q1
27 Apr 23
DGX
Earnings call transcript
2022 Q4
2 Feb 23
DGX
Earnings call transcript
2022 Q3
20 Oct 22
DGX
Earnings call transcript
2022 Q2
21 Jul 22
DGX
Earnings call transcript
2022 Q1
21 Apr 22
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 474.00 mm | 474.00 mm | 474.00 mm | 474.00 mm | 474.00 mm | 474.00 mm |
Cash burn (monthly) | 70.67 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 162.80 mm | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 311.20 mm | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 4.4 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q1 2024
86.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 767 |
Opened positions | 192 |
Closed positions | 99 |
Increased positions | 211 |
Reduced positions | 242 |
13F shares | Current |
---|---|
Total value | 12.05 tn |
Total shares | 95.66 mm |
Total puts | 435.50 k |
Total calls | 982.90 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 13.92 mm | $1.85 tn |
BLK Blackrock | 10.70 mm | $1.42 tn |
STT State Street | 5.20 mm | $692.06 bn |
Victory Capital Management | 3.92 mm | $522.10 bn |
American Century Companies | 3.87 mm | $515.63 bn |
Wellington Management | 2.61 mm | $347.79 bn |
Geode Capital Management | 2.53 mm | $336.31 bn |
Davis Selected Advisers | 2.38 mm | $316.96 bn |
Grantham, Mayo, Van Otterloo & Co. | 2.04 mm | $271.98 bn |
Dimensional Fund Advisors | 1.98 mm | $263.57 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 May 24 | Diaz Luis | Common Stock | Grant | Acquire A | No | No | 0 | 1,482 | 0.00 | 2,851 |
16 May 24 | Tracey Doi | Common Stock | Grant | Acquire A | No | No | 0 | 1,482 | 0.00 | 5,183 |
16 May 24 | Morrison Denise M | Common Stock | Grant | Acquire A | No | No | 0 | 1,482 | 0.00 | 9,490 |
16 May 24 | Wright Lassiter III | Common Stock | Grant | Acquire A | No | No | 0 | 1,482 | 0.00 | 7,709 |
News
Analyst Scoreboard: 7 Ratings For Quest Diagnostics
30 May 24
JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $155
30 May 24
How Is The Market Feeling About Quest Diagnostics?
24 May 24
Employers Struggle with Drug Test Policies Amid Varying State Laws, Cheating on Drug Tests Reaches 30-Year High
15 May 24
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
29 Apr 24
Press releases
Blood-based MRD Test for Cancer Recurrence Can Generate Cost Savings in Colorectal Cancer Treatment, Finds Study in JAMA Health Forum
31 May 24
Quest Diagnostics Elects Robert B. Carter, CIO of FedEx Corporation, to Board of Directors
16 May 24
Quest Diagnostics Declares Quarterly Cash Dividend
15 May 24
Workforce Drug Test Cheating Surged in 2023, Finds Quest Diagnostics Drug Testing Index Analysis of Nearly 10 Million Drug Tests
15 May 24
Quest Diagnostics to Speak at the 2024 Leerink Partners Healthcare Crossroads Conference
7 May 24